证券代码：600750 证券简称：江中药业 公告编号：2025-047 江中药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 8 日 (二)股东大会召开的地点：江西省南昌市高新开发区火炬大街 788 号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 908 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 301,753,931 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 47.5206 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由董事长刘为权先生主持，采取现场投票与网络投票相结合的表决方式。 表决方式符合《公司法》及《公司章程》的有关规定。 (五)公司董事、 ...

Investment Rating - The report maintains an "Overweight" rating for the traditional Chinese medicine sector [4]. Core Viewpoints - The traditional Chinese medicine sector is experiencing short-term performance pressure, but there are expectations for demand recovery in the future [7][10]. - The overall revenue and profit decline in the sector has narrowed compared to 2024, indicating a gradual recovery in industry sentiment [10]. - The report highlights the importance of brand OTC products, which are expected to see market share increases despite current demand pressures [7][26]. Summary by Sections 2025H1 Performance - In 2025H1, the total revenue of traditional Chinese medicine companies reached 172.9 billion yuan, a year-on-year decrease of 4.95% [10]. - The net profit excluding non-recurring items was 19.1 billion yuan, down 9.31% year-on-year [10]. - The operating cash flow improved significantly, reaching 16.96 billion yuan, an increase of 30.77% year-on-year [10]. OTC Market Analysis - The OTC segment is under pressure, with a median revenue growth rate of -7.6% and a net profit decline of -19.7% in Q2 2025 [26]. - The retail market for pharmaceuticals and non-pharmaceuticals in China saw a slight decline, with a total of 296.1 billion yuan in H1 2025, down 2.2% year-on-year [26][29]. - The report notes that the concentration of leading OTC brands is increasing, with significant market share gains for products like Huaren Sanjiu's Ganmaoling Granules [26][31]. Cost and Margin Outlook - The median gross margin for the sector in 2025H1 was 42.05%, a decrease of 1.01 percentage points year-on-year [10]. - The report anticipates a recovery in gross margins in H2 2025 as the pressure from high-priced raw materials eases [13]. - The median expense ratio for the sector was 44.5%, reflecting a stable cost structure despite slight increases in certain areas [15]. R&D and Innovation - The median R&D expense ratio for the sector remains around 3%, with leading companies like Kangyuan Pharmaceutical and Tian Shili investing over 10% of their revenue in R&D [24]. - The report emphasizes the potential for revaluation of innovative pipelines as companies increase their R&D investments [7].

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. is holding its first extraordinary general meeting of shareholders in 2025 to discuss key proposals including the profit distribution plan for the first half of 2025 and the reappointment of the auditing firm for the year [1][4]. Meeting Procedures - The meeting will be conducted in accordance with relevant laws and regulations to ensure the rights of shareholders and maintain order [1][2]. - Only authorized shareholders and specific invited personnel are allowed to attend the meeting, and registration is required prior to the meeting [1][2]. - Shareholders have the right to speak, inquire, and vote, but must register to speak in advance and adhere to time limits [2][3]. Meeting Agenda - The meeting is scheduled for September 8, 2025, at 14:50 in Nanchang, Jiangxi Province [1][4]. - The agenda includes the profit distribution plan for the first half of 2025 and a proposal to reappoint KPMG Huazhen as the auditing firm for 2025 [1][4]. Profit Distribution Plan - The company proposes a cash dividend of 5 yuan (including tax) for every 10 shares, which amounts to a total distribution of approximately 317.5 million yuan based on the total share capital of 634,996,022 shares as of June 2025 [4][5]. - This cash dividend represents 60.78% of the net profit attributable to the parent company for the first half of 2025 [4][5]. Auditing Firm Reappointment - The company intends to reappoint KPMG Huazhen as its auditing firm for 2025, ensuring continuity and stability in audit services [6][8]. - KPMG Huazhen has a strong track record, with over 41 billion yuan in total revenue for 2024, of which over 40 billion yuan was from audit services [6][7]. - The firm has audited 127 listed companies in 2024, with a total audit fee of approximately 682 million yuan [7][8].

2025 年第一次临时股东大会会议材料 南 昌 二〇二五年九月 江中药业股份有限公司 2025 年第一次临时股东大会会议材料 江中药业股份有限公司 江中药业股份有限公司 2025 年第一次临时股东大会会议材料 议案目录 | 议案一：公司 | 2025 | 年半年度利润分配方案 | 6 | | --- | --- | --- | --- | | 议案二：关于续聘 | | 2025 年度审计机构的议案 | 7 | 二、会议期间全体出席会议人员应以维护股东合法权益、确保大会正 常秩序、提高议事效率为原则，认真履行法定职责。 三、为保证股东大会的严肃性和正常秩序，除依法出席会议的公司股 东（或其授权代表）、董事、监事、董事会秘书、高级管理人员、聘请的 律师和董事会邀请参会的人员外，公司有权依法拒绝其他人士入场。 四、出席会议的股东（或其授权代表）必须在会议召开前十分钟向大 会秘书处办理签到、登记手续。 五、出席会议的股东（或其授权代表）依法享有发言权、质询权和表 决权等各项股东权益。股东（或其授权代表）要求发言的，应当在股东大 会召开前十分钟至大会秘书处进行发言登记，大会秘书处将按股东发言登 记时间先后顺序，安排股东 ...

Group 1 - The core viewpoint of the article highlights the significant changes in stock holdings by securities firms during the second quarter, with a focus on industries such as basic chemicals, machinery, automotive, and pharmaceuticals [1] - Securities firms collectively increased their positions in 63 stocks during the second quarter, with notable additions including Zhongke Titanium White, New Mileage, Jiangzhong Pharmaceutical, and Yuntianhua [1] - Several companies, including Chuanheng Co., Furan Energy, Ruida Futures, and Zhejiang Huaye, received attention from at least three securities firms, indicating strong interest [1] Group 2 - In terms of holding scale, data from Choice shows that Jiangsu Bank, Yong'an Futures, CITIC Securities, and Sinopec have the highest total shareholdings among securities firms [1] - As of the closing price on June 30, 2025, Jiangsu Bank leads with a holding market value of 11.026 billion yuan, followed by CITIC Securities and Yong'an Futures with 9.208 billion yuan and 6.507 billion yuan respectively [1] - Other companies such as Muyuan Foods, Cangge Mining, Sinopec, and Guangqi Technology also have significant market values in securities holdings [1]

Core Insights - The company reported a revenue of 2.141 billion yuan for the first half of 2025, a year-on-year decrease of 5.79%, while the net profit attributable to shareholders was 522 million yuan, an increase of 5.80% [1] - The company has seen a significant increase in profitability, with a net profit margin of 26.41% in Q2 2025, up by 1.03 percentage points year-on-year [3] Sales Performance - Over the first half of 2025, the company's over-the-counter (OTC) drug products generated revenue of 1.550 billion yuan, a decline of 10.14%, but with a gross margin of 76.14%, which increased by 1.09 percentage points [2] - Prescription drug products achieved revenue of 360 million yuan, reflecting a year-on-year growth of 7.44%, with a gross margin of 43.05%, up by 1.21 percentage points [2] - Health consumer products and others saw revenue of 228 million yuan, a growth of 17.35%, although the gross margin decreased by 2.04 percentage points to 38.82% [2] Profitability and Dividends - The company maintained a gross margin of 64.60% in Q2 2025, despite a year-on-year decrease of 4.79 percentage points, while the sales expense ratio improved by 10.15 percentage points to 24.72% [3] - The company declared an interim dividend of 5 yuan per 10 shares (tax included), amounting to 317 million yuan, which represents 60.78% of the net profit attributable to shareholders for the first half of 2025 [3] Investment Outlook - The company is projected to achieve revenues of 4.902 billion yuan, 5.409 billion yuan, and 5.956 billion yuan for the years 2025 to 2027, with year-on-year growth rates of 10.52%, 10.34%, and 10.11% respectively [4] - The net profit attributable to shareholders is expected to be 891 million yuan, 1.004 billion yuan, and 1.136 billion yuan for the same period, with growth rates of 12.98%, 12.80%, and 13.10% respectively [4]

Core Viewpoint - The increasing prevalence of throat diseases due to environmental pollution, lifestyle changes, and an aging population is driving the demand for throat traditional Chinese medicine (TCM), with the market expected to reach 7.4 billion yuan in 2024, reflecting a year-on-year growth of 7.49% [1][9]. Overview - Throat diseases are primarily caused by various factors such as wind-heat invasion and internal heat, leading to symptoms like sore throat and hoarseness. Throat TCM is made from traditional Chinese medicinal ingredients and is used to treat throat-related ailments, characterized by stable efficacy and minimal side effects [1][3]. Development History - The throat medicine industry in China began relatively late, with significant advancements in chronic pharyngitis research in the 1980s leading to the development of throat medications. The market was initially fragmented, but the introduction of products like Guangxi Jinsongzi's throat lozenges in 1995 marked a turning point, establishing a competitive landscape [4][5]. Market Policy - The Chinese government has implemented various policies to support the development of the TCM industry, creating a favorable environment for throat TCM growth. These include measures to enhance TCM regulation and promote innovation [5][6]. Industry Chain - The throat TCM industry consists of an upstream segment focused on medicinal herb cultivation, a midstream segment for manufacturing, and a downstream segment involving sales through medical institutions, pharmacies, and e-commerce platforms. The primary consumer groups include individuals who use their voices frequently and patients with chronic throat conditions [6][7][8]. Current Market Situation - The throat TCM market is experiencing rapid growth, with a projected sales figure of 7.4 billion yuan in 2024. Tablets represent the largest segment at 41.65%, followed by granules and pills [1][9]. Competitive Landscape - The throat TCM market is characterized by high concentration, with the top five companies holding over 50% market share in retail pharmacies. Guangxi Jinsongzi leads with a market share of 16.95% [10][11]. Key Companies - Guangxi Jinsongzi Group is a major player in the throat TCM market, with a projected revenue of 1.185 billion yuan in 2024 and a gross profit margin of 75.46% [12]. - Guilin Sanjin Pharmaceutical Co., Ltd. is another key player, with a projected revenue of 2.194 billion yuan in 2024 and a gross profit margin of 73.41% [12]. Future Trends - The throat TCM industry is expected to focus on improving the quality of raw materials and production processes to meet rising consumer demands for high-quality products. Additionally, there is potential for international market expansion, particularly in Southeast Asia, as awareness and acceptance of TCM grow [13].

Summary of Jiangzhong Pharmaceutical Conference Call Company Overview - **Company**: Jiangzhong Pharmaceutical - **Industry**: Pharmaceutical Key Financial Performance - **Revenue Growth**: 2025 H1 revenue increased by 5.8% to 21.41 billion CNY, despite a 5.79% year-on-year decline in total revenue [2][4] - **Operating Cash Flow**: Increased by 29.07% to 652 million CNY [2][4] - **Profitability**: Total profit rose by 12.01% to 705 million CNY, with net profit attributable to shareholders increasing by 5.8% to 522 million CNY [4] Business Segment Performance - **OTC Business**: Revenue decreased by approximately 10% to 1.55 billion CNY [2][4] - **Health Consumer Products**: Revenue grew by 17.35% to 228 million CNY [2][4] - **Prescription Drugs**: Revenue increased by 7.44% to 360 million CNY [2][4] Strategic Focus Areas - **Core Business Segments**: Focus on OTC, health consumer products, and prescription drugs, driven by brand and innovation [2] - **Digital Transformation**: Emphasis on digital marketing and data analytics, including the introduction of AI tools for data processing [2][8] - **Talent Development**: Strengthening talent management and integrating resources to support innovation, with over 50% of the second incentive plan covering core scientific talent [3][10] Operational Initiatives - **Smart Manufacturing**: Advancements in smart manufacturing and lean management to enhance production efficiency [7] - **Marketing Strategies**: Strengthening online and offline channel collaboration, with a focus on e-commerce platforms like JD and Alibaba [5][12] - **Product Development**: Continuous innovation in product offerings, particularly in the health consumer segment [6][21] Future Outlook - **2025 H2 Plans**: Continued focus on value creation and brand-driven growth, with an emphasis on new product development and market expansion [11][19] - **Market Adaptation**: Strategies to adapt to market pressures, including effective cost management and exploring external growth opportunities [17][18] Additional Insights - **Digital Marketing**: Enhanced digital marketing efforts to reach younger demographics and improve brand recognition [20] - **Product Positioning**: Adjustments in product positioning and pricing strategies to attract a broader consumer base [22] - **Long-term Goals**: Commitment to high-quality development and shareholder value creation as part of the transition from the "14th Five-Year Plan" to the "15th Five-Year Plan" [23]

Core Viewpoint - The company demonstrates resilience in a challenging OTC market, with a focus on growth in health consumer products and prescription drugs, while maintaining strong profitability and cash flow [1][2][3]. Group 1: Company Performance - In the first half of 2025, the company reported revenues of 2.14 billion yuan, a decrease of 6% year-on-year, while net profit attributable to shareholders increased by 6% to 520 million yuan [1]. - The second quarter of 2025 saw revenues of 960 million yuan, down 4% year-on-year, but net profit attributable to shareholders rose by 6% to 240 million yuan [1]. - The decline in revenue is primarily attributed to changes in OTC demand, but the company has optimized costs and expenses, leading to improved profitability [1]. Group 2: Industry Context - The pharmaceutical manufacturing industry in China faced a 1.2% decline in revenue and a 2.8% drop in profit in the first half of 2025 [2]. - OTC revenue for the company fell by 10% year-on-year to 1.55 billion yuan, while health consumer products grew by 17% to 230 million yuan, and prescription drug revenue increased by 7% to 360 million yuan [2]. Group 3: Profitability and Cash Flow - The gross margin for the first half of 2025 was 66.6%, a decrease of 2.4 percentage points year-on-year, mainly due to a lower proportion of high-margin OTC business [3]. - The company maintained a weighted average return on equity of 12.89%, an increase of 1.02 percentage points year-on-year, indicating sustained improvement in profitability [3]. - Operating cash flow net amount was 650 million yuan, while investment cash flow net amount was -330 million yuan, reflecting stable cash flow management [3]. Group 4: Dividend Policy - The company plans to distribute a cash dividend of 0.5 yuan per share, representing 60.78% of the net profit attributable to shareholders for the first half of 2025 [4]. - The company emphasizes high shareholder returns, maintaining a policy of two cash dividend distributions annually during the 14th Five-Year Plan period [4]. Group 5: Investment Outlook - The company maintains a profit forecast, expecting net profits attributable to shareholders of 897 million yuan, 1.015 billion yuan, and 1.145 billion yuan for 2025-2027, representing year-on-year growth of 14%, 13%, and 13% respectively [5]. - A target price of 29.96 yuan is set based on a 21x PE ratio for 2025, maintaining a "buy" rating [5].

Core Viewpoint - Jiangzhong Pharmaceutical (600750) reported a mixed performance in its 2025 mid-year financial results, with a net profit increase of 5.8% despite a decline in total revenue by 5.79% compared to the previous year [1] Financial Performance Summary - Total revenue for the first half of 2025 was 2.141 billion yuan, down 5.79% from 2.273 billion yuan in 2024 [1] - Net profit attributable to shareholders reached 522 million yuan, up 5.8% from 494 million yuan in the previous year [1] - The gross profit margin was 66.6%, a decrease of 0.64% year-on-year, while the net profit margin improved to 26.13%, an increase of 11.42% [1] - Total operating expenses (sales, management, and financial expenses) amounted to 694 million yuan, accounting for 32.42% of revenue, down 11.97% year-on-year [1] - Earnings per share (EPS) increased to 0.82 yuan, up 3.8% from 0.79 yuan [1] Cash Flow and Asset Changes - Operating cash flow per share improved by 27.88% to 1.03 yuan [1] - Cash and cash equivalents increased by 33.53% to 1.529 billion yuan, attributed to an increase in large bank deposits maturing within one year [1][2] - Trade receivables rose significantly by 79.86% to 500 million yuan [1] - The company saw a dramatic increase in interest-bearing liabilities, up 15,389.60% to 158 million yuan [1] Investment and Financial Strategy - The company has increased its investment in financial products, leading to a 1399.59% rise in trading financial assets [2] - The construction in progress increased by 42.67%, indicating ongoing investment in the Jinjiang Industrial Park project [2] - The company reported a significant increase in other income by 131.95%, primarily due to government subsidies received [4] Market Position and Future Outlook - Analysts project that Jiangzhong Pharmaceutical's performance for 2025 will reach 897 million yuan, with an average EPS forecast of 1.41 yuan [5] - The company has a strong return on invested capital (ROIC) of 17.24%, indicating robust capital efficiency [4] Fund Holdings - The largest fund holding Jiangzhong Pharmaceutical is the GF Stable Growth Mixed Fund, with 15 million shares held [6] - The fund's recent performance shows a net asset value increase of 9.19% over the past year [6]